 |
 |
 | | | Tuesday 13:th May 2008 | Vitaflo licenses world wide rights for two products in Medical Nutrition | Vitaflo licenses world wide rights for two products in Medical Nutrition
(Lysaker, Norway, 6 May 2008) Navamedic\'s subsidiary Vitaflo Scandinavia AB and the Swedish corporation Lantmännen AS – Faktor AB have signed an agreement for the products SPC- Flakes and Salovum. Vitaflo will have the rights to market and sell the products world wide from July 2008. Both products fall within the knowledge area Medical Nutrition and fit well into the company’s existing product portfolio.
- We are extremely satisfied with the possibility to broaden our already large product portfolio with these products. With our knowledge, broad experience and world wide contacts within Medical Nutrition, we believe we can market the products in a satisfying way for both parties, says Øyvind Brekke, CEO in Navamedic ASA.
- With our long and successful presence within the area Metabolic Nutrition, we are well prepared for this challenge and we are thrilled by the interesting possibilities this project opens, says Tina Madsen, CEO for Vitaflo.
Swedish scientists were the first to discover the Antisecretory protein, Factor AF, an endogenous protein found in all living species, including the human body, regulating the body’s secretory and Ion balance. Scientists have found and documented, in a long row of Clinical studies, that people suffering from IBD, Mb Meniere and severe diarrhoea, have low amounts of protein AF. Both Swedish and international studies have shown that SPC-Flakes and Salovum can be used effectively of regulating the level of protein AF to therapeutic levels.
- Both products have shown effect in a number of clinical studies in Sweden and abroad, and are subject to patents all over the world, says Lars Sjöstrand, CEO for Lantmännen AS-Faktor AB.
SPC-Flakes is used in the treatment of inflammatory bowel disease (IBD) and Mb Ménières disease causing dizziness. Salovum is effective in the acute treatment of inflammatory and secretory conditions.
-Each year, diarrhoea causes the death of about five million children world wide. Therefore, I am happy to announce that in Pakistan, the treatment with Salovum gave significant improvements on children with severe diarrhoea, says Lars Sjöstrand.
Vitaflo will have the responsibility for the sales and marketing of SPC-Flakes and Salovum world wide from July 2008. Vitaflo will sell the products in markets where Vitaflo is already present and through well known partners elsewhere. The products are currently on the market in Sweden. Without any marketing efforts, the products sold for SEK 4 million in 2007.
The agreement has an initial duration of 4 years and may be prolonged. Lantmännen AF - Faktor AB and Vitaflo Scandinavia AB are interested in a long term agreement and Vitaflo will not pay any up-front payments or license fee for the rights.
The products are classified as food for special medical purpose. The patents last until 2014, 2016 respectively, and new patent applications are filed 2006.
Navamedic is a fast-growing specialty pharma company. The company is well underway with the international commercialization of its osteoarthritis medication Glucomed. In 2006, Glucomed was the first glucosamine product approved by European authorities for marketing as a drug in all EU countries. Through the acquisition of Vitaflo Scandinavia AB in 2007, Navamedic initiated an expansion of its strategy to include marketing of pharmaceutical products in selected countries. Vitaflo represents more than 45 products from over 20 foreign companies on the Nordic markets, and has shown significant revenue growth over the last 5 years. Navamedic aspires to grow both through increased geographical presence and through a broadened product portfolio within selected therapeutic areas. In addition to organic growth, the company will continue to evaluate further company and/or product acquisitions.
For further information, please contact:
Tina Madsen, CEO, Vitaflo Scandinavia AB
E-mail: tina.sandstrom@vitaflo.net
Office: +45 48 22 18 38
Mobile: +421 64 00 145
Roland Sandström, COB, Vitaflo Scandinavia AB
E-mail: roland.sandstrom@vitaflo.net
Office: +46 31 335 11 90
Mobile: +46 70 5925622
Lars Sjöström, CEO Lantmännen AS Factor AB
Email: lars.sjostrand@lantmannen.com
Office: +46 8 6574267
Mobile: +46 0705 625650
|
|
| | | Friday 14:th March 2008 | New in-licensing agreement | 14/03-2008 10:32:00:New in-licensing agreement
Vitaflo Scandinavia AB has signed an agreement with Mekos (Denmark)and Smart Practice (Canada) for marketing of the product line Allergeaze in Denmark, Finland, Norway, Sweden and Iceland. This agreement fits well into the Company\\\'s strategy to expand the product portfolio in selected knowledge areas. The products fall into the knowledge area dermatology where Vitaflo Scandinavia is already present with several products. With the new product line Allergeaze Vitaflo Scandinavia will be the leading distributor for products for patch testing allergic contact dermatitis. Today Vitaflo Scandinavia is present in this field with the pharmaceutical product TrueTest/MekosTest produced by Mekos.
The current market size for the targeted market is approximately SEK 10 million. The Allergeaze product line is ready to be launched at the marked in Denmark, Finland, Norway, Sweden and Iceland. The agreement has an initial duration of 2 years and may be prolonged for additional 2-year periods.
Tina Madsen Sandström, CEO of Vitaflo Scandinavia, said: I am very pleased with the extension of the cooperation with Mekos as Dermatology is one of our prioritized knowledge areas. With the possibility to offer both a standardised pharmaceutical product for patch testing and now single allergens we will have a very strong position in the Nordic market.
Susanne Munksted sale- and marketing director of Mekos; Vitaflo Scandinavia AB have successfully represented our product TrueTest/MekosTest in the Scandinavian markets since 2004. We value our co-operation and look forward to extending this when including Allergeaze in the portfolio. We are certain that Vitaflo will use best efforts when introducing Allergeaze and look forward to continue our collaboration
|
|
| | | Tuesday 9:th October 2007 | Initiates a new strategic phase for Vitaflo - Navamedic ASA completes the acquisition of Vitaflo Scandinavia AB | On 4 October, Navamedic ASA completed the acquisition of 100% of the shares in the Swedish pharmaceutical company Vitaflo Scandinavia AB from POA Consulting Scandinavia AB, and takes the first step towards the creation of an international speciality pharmaceutical company.
Navamedic, and Vitaflo Scandinavia (Vitaflo) is the start of a new and exciting strategic phase. The aim is to become an international speciality pharmaceutical company. Vitaflo, with its increasing product portfolio in selected growth areas gives a strong platform to build upon.
Vitaflo markets a wide portfolio of own and in-licensed products in Norway, Denmark, Sweden, Finland, Holland, and Iceland, and has further growth ambitions. The portfolio consists of 44 products in 10 knowledge areas, whereof Metabolic Diseases, Oral Medicine and Female Care are expected to be the most important going forward.
Navamedic paid SEK 90 million for Vitaflo Scandinavia AB (enterprise value), of which SEK 54 million in cash and SEK 36 million in the Navamedic shares resolved issued 4 October 2007. The purchase agreement consists of an earn-out model based on achieved EBITDA for Vitaflo Scandinavia AB in 2007.
On 4 October 2007, with a contribution in kind of 40% of the shares in Vitaflo, the Board of Directors in Navamedic resolved to issue 672.213 new shares in Navamedic to the seller of Vitaflo, POA Consulting Scandinavia AB, to a price of NOK 44,90 per share.
After the registration of these capital increases, POA Consulting Scandinavia AB will own 672.213 shares in Navamedic ASA, corresponding to 8,92% of the 7.537.051 shares in the company.This makes POA Consulting the biggest owner group of Navamedic ASA. POA Consulting Scandinavia AB is owned by among others RolandSandström (56,1%) and Tina Madsen Sandström (9,75%). Roland Sandström was 6 September 2007 elected as a board member in Navamedic ASA, effective from 4 October 2007.
Trading of the new shares is expected on Oslo Stock Exchange from 8 October 2007.
|
|
| | | Thursday 23:rd August 2007 | On 21 August Navamedic ASA entered into an agreement with POA Consulting Scandinavia AB | (Lysaker, 22 August 2007): On 21 August Navamedic ASA entered into an agreement with POA Consulting Scandinavia AB concerning the acquisition of the
Swedish speciality pharmaceutical company Vitaflo Scandinavia AB At the same time, by a new share issue, POA Consulting Scandinavia AB will be a mayor shareholder of the Navamedic/Vitaflo group.
For Vitaflo there will be no change in management or organistaion and the business is to continut as.
We see a lot of advantages with this exciting opportunity as mentioned above but also to add financial muscles (more marketing!) and an in-house regulatory department.
Vitaflo will with this exiting cooperation being able, to focus on continues growth for the group, in the Nordic area as well as outside that region.
We will be able to offer, to our principals, a regulatory department in house and we will be able to invest in even more marketing resources than before.
“The acquisition of Vitaflo is the first step towards the creation of an international speciality pharmaceutical company, where Navamedic will provide valuable qualifications registration and approval processes and an international network within distribution/marketing. The acquisition does not change Navamedic’s ambitions in the glucosamine market, where the focus on Glucomed/Flexove will continue with full intensity through existing distributions agreements.
The acquisition of Vitaflo is the first step towards the creation of an international speciality pharmaceutical company, and a natural step for Navamedic now that we see glucosamine entering into the commercial phase. We have gained strong experience within registration of pharmaceutical products in Europe and developed a large network within distribution and marketing both inside and outside of Europe, says CEO Øyvind Brekke in Navamedic.
-We wish to utilize this capacity for commercializing additional products. Further, we wish to use the new structure in the company as a platform for further development, through organic growth, and through the acquisition of complementary product portfolios and/or companies if we can find good opportunities.
- Navamedic will be an very good industrial owner for us. Together we can make the Scandinavian and European markets far more accessible for pharmaceutical companies overseas, which face heavy registration processes and a fragmented market structure which are considered as restrains on their expansion plans. The new structure is fully in line with the long-term expansion strategy in Europe which Vitaflo hastargeted on its own, says Roland Sandström in Vitaflo Scandinavia AB.
|
|
| | | Monday 12:th March 2007 | Annual report 2006 | | For the 6th year Vitaflo increases the turnover with more than 60%. The Net profit increased with 220 %. |
|
| | | Monday 12:th March 2007 | Distribution and strategic Marketing cooperation. | A distribution agreement between Medtech, NO and Vitaflo regarding Snoreeze in Norway from 2006, has been signed.
Medtech will amarket Snoreeze through their channels. |
|
| | | Monday 12:th March 2007 | Distribution and Strategic marketing cooperation | A distribution agreement between Hela Pharma and Vitaflo regarding Herstat in Sweden from November 2006, has been signed.
Hela Pharma will also market Vitaflo´s product Snoreeze through their channels. |
|
| | | Monday 12:th March 2007 | Distribution Agreement | | A distribution agreement between Vitaflo and Special Products, UK, regarding Special Products areas Neurology and Metabolism, has been signed for Denmark, Norway, Sweden and Finland. |
|
| | | Monday 12:th March 2007 | Marketing Cooperation | | A marketing cooperation regarding marketing of Vitaflo Products in Finland has been agreed between Bottnia OY and Vitaflo from January first. |
|
| | | Friday 16:th June 2006 | Announcement | AnnouncementAs from the first of AprilAs from the first of April Roland Sandström, now Managing Director and Chairman of the Board of Vitaflo Scandinavia AB will act as full time Chairman of the Board with specific operative responsibilities for New Projects and International Business.
Roland Sandström. Born 1946. Founder and majority share holder of Vitaflo Scandinavia AB. Master of Political Science. Studies in Business Economy at the University of Lund. Articles, lectures and books (The Customer as a Friend) in organisation theory and marketing. 30 years experience within the International Pharmaceutical Industry in different positions. Final position before founding Vitaflo Scandinavia AB, Managing Director for Meda Sweden AB. Former board member of LSAB and LIF. Founder of “The Global Healthcare Network”.
AnnouncementAs from the first of AprilAs from the first of April Mrs Tina Madsen, today Country Manager for Denmark, will be appointed Managing Director of Vitaflo Scandinavia AB. Tina will keep her
responsibilities for the company’s operations in Denmark and Holland.
Tina Madsen. Born 1965. Shareholder and board member of Vitaflo Scandinavia AB. Merkonom, Educated at Hillerød Business School. 20 years experience within the Pharmaceutical Industry in different positions. Final position before joining Vitaflo Scandinavia AB – Managing Director for Pharma-Vinci A/S.
AnnouncementAs from the first of AprilAs from the first of April Anders Bergström will be appointed Country Manger for Sweden.
Anders Bergström. Borne 1956. Shareholder and board member of Vitaflo Scandinavia AB. 20 years experience within the Pharmaceutical Industry. Bachelor’s degree in Business Economy and Biochemistry. Final position before Vitaflo Scandinavia AB, Business Unit Manager at Meda OTC department.
AnnouncementAs from the first of AprilAs from the first of April Hans Magne Ellingsen will be appointed Country Manager for Norway.
Hans-Magne Ellingsen. Born 1953. Bioengineer from University hospital in Bergen. Business economy NKI. 14 years within the Pharmaceutical industry in different positions. Final position before Vitaflo – Sales and Marketing Manager Galderma Norway.
AnnouncementAs from the first of AprilAs from the first of April Valdet Hetemi will be appointed as Back-Up officer reporting directly to the Management of the group, with specific responsibility for economy and logistics.
Valdet Hetemi. Born 1978. Master in Business Administration. Studies in Business Administration, Economics and German at the University of Lund with a major in Strategic and Cost Management. Has also studied Business Administration and Economics at the University of Cologne in Germany. Valdet joined Vitaflo in September 2004.
|
|
| | | Friday 16:th June 2006 | Distribution Agreement | A distribution agreement between Vitaflo Scandinavia AB and Passion For Life, Epsom, UK, has been signed, June 2006 regarding marketing and distribution of Snoreeze in Denmark, Norway and Sweden.
For further information, please contact Roland Sandström, Vitaflo or Alexander Duggan, Passion for Life
|
|
| | | Friday 16:th June 2006 | Distribution Agreement | | A Distribution Agreement has been signed between Vitaflo Scandinavia AB, Arsenal Holdings Ltd, Lugano, Switzerland and Three Rivers Pharmaceuticals Commerce Park Drive, Cranberry Township, regarding marketing and distribution of Amphocil in the Nordic area. The agreement is effective from May 2006. |
|
| | | Friday 16:th June 2006 | Distribution Agreemnt | A distribution Agreement between Vitaflo Scandinavia AB and Mirwana, Gällivare, Sweden, regarding Drop-it in Denmark, has been signed March 2006
For further information ,please contact Tina Madsen, Vitaflo or Lars Skoglund, Mirwana.
|
|
| | | Friday 16:th June 2006 | Marketing Agreement | An agrement regarding marketing and distribution of the Dentofix line in Scandinavaia, between Vitaflo Scandinavia AB and ISP (GB)has been made. The agreement is valid from January 2006.
For further information contact Tina Madsen Vitaflo Scandinavia AB. |
|
| | | Friday 16:th June 2006 | Distribution Agreement | A Distribution agreement has been signed December 2005 between Vitaflo Scandinavia AB and SBL Vaccines AB,Solna, Sweden, regarding distribution of Dukoral, Epaxal and Vivotif in Denmark.
For more information please contact Roland Sandström, VItaflo Scndinavia or Stefan Folkesson, SBL.
|
|
| | | Thursday 13:th October 2005 | Vitaflo sign new contract for IEM in Holland | Vitaflo Scandinavia AB signs a new contract with Vitaflo Int., Liverpol, UK, regarding marketing and distribution of IEM products in Holland.
The existing contract for Denmark, Finland, Island, Norway and Sweden has been prolonged with 10 years.
For more information please contact Roland Sandstrøm,CEO Vitaflo Scandinavia or Tony Partington,CEO Vitaflo Int.
For moree information about Vitaflo Int. |
|
| | | Friday 2:nd September 2005 | Distribution Agreement | A Distribution agreement has been signed between Vitaflo Scandinavia AB and Nutrichem Diät+PharmaGmbH, Roth, Germany, regarding distribution of Enteral Nutrition products in Scandinavia. Nutrichem Website.
For more information please contact Roland Sandström, VItaflo Scndinavia or Bernd Kartsen, Nutrichem. |
|
| | | Wednesday 10:th August 2005 | Distribution Agreement | A Distribution agreement has been signed between Vitaflo Scandinavia AB and BIOPLAX LIMITED, a United Kingdom Limited Company, regarding distribution of the Aftamed products in Sweden, Denmark, Norway, Finland and Island. For more information please contact Roland Sandström, CEO Vitaflo Scandinavia AB.
|
|
| | | Wednesday 10:th August 2005 | Distribution Agreement | | A Distribution Agreement has been signed between Vitaflo Scandinavia AB and Arsenal Holdings Ltd, Lugano, Switzerland, regarding distribution of generic products within Antibiotics, Cancer, Gastro,Opthamology for Sweden, Denmark, Norway, Finland, the Baltic area and Island. For more information please contact Roland Sandström, CEO Vitaflo Scandinavia AB or Jens Rygard, President Arsenal. |
|
| | | Wednesday 10:th August 2005 | Distribution Agreement | A Distribution Agreement has been signed between Vitaflo Scandinavia AB and KV Pharmaceutical Company, based in St. Louis, USA, for the granting of licensing rights in Sweden, Denmark, Norway, Finland and Island for KV’s two single-dose treatment prescription vaginal cream products, U.S. market leader Gynazole-1® and the recently FDA approved Clindesse™. For more information please contact Roland Sandström, CEO Vitaflo Scandinavia AB or Daniel J. Thompson, M.S.Director, Medical Affairs or
Mr. Mitch Kirschner, Vice President of Business Development, KV Pharmaceutical.Website of KV Pharnmaceutical |
|
| | | Sunday 24:th July 2005 | Network Organisation | | Vitaflo/POA has entered as a member of the international network organisation, Global Healthcare Network GHN. The organisation was founded by Roland Sandström CEO for POA/Vitaflo. GHN is a non-profit organisation with, today, 13 members from 11 countries. The members have all an experience from top positions within the international Pharmceutical industry. |
|
| | | Friday 29:th April 2005 | Distribution Agreement | A Distribution Agreement has been signed between Vitaflo Scandinavia AB and Phoenix Dental Inc, Fenton, Michigan, USA, regarding distribution of SuperSeal in Sweden, Denmark, Norway, Finland and Island. For more information please contact Roland Sandström, CEO Vitaflo Scandinavia AB or Jeffrey S. Cox, President Phoenix Denatl Inc.
|
|
| | | Wednesday 5:th January 2005 | License and Distribution Agreement | A LICENSE AND DISTRIBUTION AGREEMENT has been signed between VITAFLO SCANDINAVIA AB and NECURA Pharmaceuticals AG, Basel, Switzerland, dated 29.12.2004, regarding FemiFect® and all Line-extensions, for Sweden, Denmark, Finland and Island.
For more information contact Roland Sandström, CEO Vitaflo or Cees Winnips M.D.CEO, Necura Pharmaceuticals AG
CH4051 Basel, Switzerland.
|
|
| | | Monday 25:th October 2004 | Distribution Agreement | A Distribution Agreement has been signed between Vitaflo Scandinavia AB and Arriani Pharmaceuticals SA, Athens, GREECE regarding distribution and sale of Vitaflo CHX in Greece and Cyprus.
The Chewing gum will be sold under the brand name of SOLU-GUM.
|
|
| | | Saturday 16:th October 2004 | Court proceedings | In a trial at the Maritime and Commercial court in Copenhagen (Sø- och Handelsretten), a former principal to Vitaflo Scandinavia AB, Pharma Vinci A/S, was judged to pay Vitaflo 956.738 SEK plus interest rate since February 2002, as a compensation for breach of contract before the stipulated period.
Furthermore Pharma-Vinci had to pay all court proceedings.
|
|
| | | Tuesday 5:th October 2004 | Distribution Agreement | A Distribution Agreement has been signed between Vitaflo Scandinavia AB and AOP Orphan Pharmaceuticals AG Wien, Austria regarding distribution in Scandinavia from October 5,2004.
For more information please contact Roland Sandström, CEO Vitaflo Scandinavia AB or Dr. Widmann, CEO AOP Orphan Pharmaceuticals AG.
|
|
| | | Thursday 1:st July 2004 | Distribution Agreement | A Distribution Agreement has been signed between Vitaflo Scandinavia AB and Chattem, Inc. regarding distribution of SELSUN in Scandinavia frm July 1, 2004.
For more information about Chattem, se link below.
Selsun has earlier been distributed by Abbot in Scandinavia.
The Product:SELSUN®, a liquid antiseborrheic, antifungal preparation for topical application.
To see a picture of the product, go to www.vitaflo.net/Gallery/products.
Chattem[img][img] |
|
| | | Thursday 1:st July 2004 | Distribution Agreement | A Distribution Agreement has been signed between Vitaflo Scandinavia AB and Ziwell Medical(S) PTE Ltd regarding Vitaflo CHX for Singapore and Malaysia.
|
|
| | | Sunday 4:th January 2004 | Distribution Agreement | A Distribution Agreement has been signed between Vitaflo Scandinavia AB and Medical & Devices GmbH regarding Vitaflo CHX in Germany and Austria.
The Chewing gum will be sold under the brand name of Hexit.
|
|
| | | Sunday 4:th January 2004 | Supply Agreement | A Supply Agreement has been signed between PharmAlliance International Ltd and Fertin Pharma A/S, regarding export of a Chlohexidine Chewing Gum for Germany, Austria, Greece, Italy, France, Spain, Portugal, Israel and Singapore.The Suply Agreement includes Vitaflo Scandinavia AB as being the operational partner for PharmAlliance International Ltd.
The Chlorhexidine Chewing gum is already sold in Sweden, Denmark and Finland under the brand name of Vitaflo CHX.
PhamAlliances International. Ltd |
|
| | | Monday 15:th December 2003 | Distribution Agreement | A contract has been signed between Mekos Laboratories AS and Vitaflo Scandinava AB, regarding the marketing and distribution of True Test for Scandinavia from January 1, 2004.
What is TRUE Test™ ?
TRUE Test™ (Thin-layer Rapid Use Epicutaneous Test) is a ready-to-use patch test system for diagnosis of allergic contact dermatitis.
Allergic contact dermatitis is an inflammatory reaction that occurs when substances to which you are allergic come in contact with your skin. These substances could be an ingredient in your perfume or aftershave, an antibiotic ointment or cream, rubber boots etc.
Mekos Laboratories AS is a new Danish pharmaceutical niche company specialized in the field of contact allergy testing.
The company was established on January 1, 2001 based on a management-buy-out of Pharmacia & Upjohn Hillerød AS in Denmark from the multinational pharmaceutical group, Pharmacia Corporation Inc. The acquisition included the global business and all other assets relating to a patented test system for contact allergy, TRUE Test®.
The operations of the company are focused on R&D/production and TRUE Test® is marketed and distributed on the global market by a network of local distributors/licensees in more than 25 countries with US and Europe as primary markets at present.
For more information contact Roland Sandström CEO at Vitaflo Scandinavia AB or Bo Poulsen CEO Mekos Laboratories AS.
Mekos Laboratories.AS |
|
| | | Wednesday 5:th February 2003 | New Offices in Danmark | | New Offices in Danmark From February 15 th, Visiting address is Langesvej 2 A, 3400 Hilleröd. Box address, Tel. And Fax are the same as before. |
|
| | | Wednesday 1:st January 2003 | Launch | Superseal is introduced to the Swedish market, Jan/Feb.
Bifolac is introduced to the Swedish market,Feb/March
Periochip will be introduced to the Finnish market, Feb./March.
VitaKalk will be introduced to the Swedish market. |
|
| | | Wednesday 1:st January 2003 | Letter of Intent | | A letter of Intent A has been signed between Vitaflo Scandinavia AB and SBL vaccine AB, regarding marketing of their vaccines in Denmark. The marketing cooperation will start 1st of February 2003 and include Epaxal, Dukoral and Vivotif. |
|
| | | Tuesday 3:rd December 2002 | Launch | | PKU Express from Vitaflo int. is introduced to the Swedish, Danish and Norwegian markets. |
|
| | | Wednesday 27:th November 2002 | New Agreement | | A New Agreement has been signed between Dexcel and Phoenix dental and Vitaflo regarding the marketing rights for SuperSeal. |
|
| | | Wednesday 27:th November 2002 | Launch | | Periochip from Dexcel is introduced to the Norwegian market. |
|
| | | Thursday 19:th September 2002 | Launch | | Bettamousse from Celltech is introduced to the Norwegian market. |
|
| | | Thursday 15:th August 2002 | Marketing cooperation | | A cooperation regarding Vitaflo CHX and Periochip has been established between D 34 and Vitaflo regarding the Danish market. |
|
| | | Friday 3:rd May 2002 | Launch | EcoVag from Bifodan is introduced to the Danish market.
Periochip from Dexcel is introduced to the Danish market. |
|
| | | Monday 11:th February 2002 | Appointments | From February Tina Madsen Sandström has been appointed Managing Director for Vitaflo Denmark. Tina Madsen Sandström latest position was as Managing Director for Pharma-Vinci A/S.
|
|
| | | Monday 11:th February 2002 | New Agreement | A New Agreement has been signed between Bifodan A/S and Vitaflo, regarding the marketing rights for Bifolac and products in pipe-line for Denmark and Sweden.
A New Agreement has been signed between Dexxon and Vitaflo regarding cooperation regarding Periochip. in Denmark, Norway and Finland. Since 2001 there exists a New Agreement regarding Sweden. |
|
| | | Thursday 4:th October 2001 | The board | | The board of POA/Vitaflo has voted Tina Madsen Sandström as a new member. The board consists of Roland Sandström (CEO vitaflo/POA Scandinavia AB), Dir. Anders Bergström, Professor Ingvar Borsaeus, Dr BO Ahrenfelt and Dir. Sture Lans. |
|
| | | Thursday 4:th October 2001 | Customer Service | | MIN SIDA a service site containing news from the Health Care sector is introduced. |
|
| | | Monday 6:th August 2001 | Launch | | Periochip from Dexcell is introduced to the Swedish market. |
|
| | | Friday 9:th March 2001 | Vitaflo moves to new offices in Sweden | Vitaflo Scandinavia AB
www.vitaflo.net / info@vitaflo.net
Ebbe Lieberathsgatan 21;
412 65 Göteborg
Box 53065
400 14 Göteborg
Sweden
Tel: +46 31 335 11 90
Fax: +46 31 335 11 99 |
|
| | | Thursday 8:th February 2001 | Symposium | | Nordic Symposium around Inborn Error of Metabolism. Participation of dieticians from Sweden, Denmark, Norway and UK. |
|
| | | Thursday 8:th February 2001 | New Agreement | | New Agreement signed between Evans Ltd. And Vitaflo regarding Fluvirin. Fluvirin is a Flue vaccine. |
|
| | | Monday 22:nd January 2001 | New Agreement | Distribution Agreement signed between Dexxon and Vitaflo regarding Periochip. Periochip is a registered pharmaceutical specialty for the treatment of peridontitis.
|
|
| | | Friday 4:th February 2000 | Symposiaum | The yearly Vitaflo symposia in Gothenburg this year, has the title \"Management By Love\", and will take place September 29 in the concert hall.
Chairman for the symposium is Professor Edgard Borgenhammar.
Other lecturers are dr. Margareta Andersson, Vikar Ulla-Britt Berglund, dr Rolf Ahlzen and professor Bodil Jönsson.
Free participation. Read more and book at our web side - Vitaflo.net/Company/activities. |
|
| | | Friday 5:th November 1999 | New Board members | | Assistant professor Ingvar Borseus, Gothenburg and Dr Bo Ahrenfeldt Vaxjo. Both of them will, with their long experience within the Scandinavia Health Care sector, substantially contribute in the growth process of the company. |
|
| | | Friday 5:th November 1999 | Letter Of Intent | | A letter of intent has been signed between Vitaflo/POA and Fertin regarding a Chlorhexidine chewing gum for Scandinavia. More or less all people over the age of 40 has problems with Gingivitis and their exists today no Chlorhexidine chewing gums within the Scandinavian market. Fertin , a Company within the Danish Dandy group, is the world leading company in developing medical chewing gum. |
|
| | | Friday 5:th November 1999 | Launching | | During October Vitaflo has launched Bettamousse in Sweden and Denmark. Bettamousse is a new concept for treatment of Psoriasis in the Scalp. Producer is The English Pharmaceutical Company Medewa and the product is a type of group three steroids in mousse form. Introduction to the Finnish market will be made during November.Medewa is the fourth biggest Pharmaceutical company in UK. |
|
|
| Copyright Reserved® |
